Valuation: Avicanna Inc.

Market Cap 16.22M 11.43M 10.03M 9.24M 8.65M 1.08B 16.56M 111M 42.98M 533M 42.94M 42M 1.85B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 15.94M 11.24M 9.85M 9.08M 8.5M 1.06B 16.27M 109M 42.24M 524M 42.19M 41.27M 1.82B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day-2.55%
1 week-4.17%
Current month-6.59%
1 month-8.90%
3 months-27.60%
6 months-46.88%
Current year-47.56%
1 week 0.08
Extreme 0.0849
0.09
1 month 0.08
Extreme 0.075
0.11
Current year 0.08
Extreme 0.075
0.18
1 year 0.08
Extreme 0.075
0.24
3 years 0.08
Extreme 0.075
0.53
5 years 0.08
Extreme 0.075
1.24
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-4.17% - - 11.43M
-0.48%+8.75%-5.51%+0.91% 46.36B
+2.19%+9.81%+385.81%+632.13% 37.88B
+2.53%+13.90%+20.85%-10.61% 31.12B
+1.65%+2.98%+9.98%+55.42% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-0.32%+14.36% - - 16.25B
+1.37%+15.67%+71.80%+134.14% 14.85B
+1.00%+9.67%+14.90%+21.88% 13.58B
+3.63%+6.97%+104.07%+107.62% 12.95B
Average +0.40%+7.85%+76.30%+119.69% 25.36B
Weighted average by Cap. +0.59%+7.66%+85.55%+138.80%

Financials

2024 2025
Net sales 25.46M 17.94M 15.73M 14.5M 13.58M 1.69B 25.99M 174M 67.45M 837M 67.38M 65.91M 2.9B 25.48M 17.96M 15.75M 14.51M 13.59M 1.69B 26.01M 174M 67.5M 837M 67.43M 65.96M 2.9B
Net income -3.62M -2.55M -2.24M -2.06M -1.93M -241M -3.69M -24.77M -9.58M -119M -9.57M -9.37M -412M -2.76M -1.94M -1.71M -1.57M -1.47M -183M -2.82M -18.89M -7.31M -90.66M -7.3M -7.14M -314M
Net Debt -339K -239K -209K -193K -181K -22.53M -346K -2.32M -898K -11.13M -897K -877K -38.6M -281K -198K -173K -160K -150K -18.66M -286K -1.92M -743K -9.22M -743K -726K -31.97M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
27/06/26 US$0.0850 -2.55% 42,750
25/06/26 US$0.0872 -1.45% 2,000
24/06/26 US$0.0885 -3.49% 113,600
23/06/26 US$0.0917 +3.38% 194,350
22/06/26 US$0.0887 -3.69% 147,250